- Bacterial Biofilm is a confounding factor in the pathogenesis of Breast Implant Illness
- The Oxylipid10-HOME can detect the presence of bacterial biofilm in tissue surrounding implants.
- The synthesis of 10-HOME has been optimized for commercialization.
Silicone breast implants, first introduced in 1962, represents over a billion-dollar market but their safety has been a source of controversy. Breast implant illness (BII) is a term used to refer to a wide range of symptoms that can develop after undergoing breast reconstruction or augmentation with breast implants. Bacterial biofilms have a role as a confounding factor in the pathogenesis of BII. Biofilm protects bacteria from detection and eradication, and the biofilms themselves are hard to detect because of the lack of biofilm-specific biomarkers. However, bacteria in the biofilm interact with host lipids, which leads to the formation of oxylipins. Detection of oxylipins in tissue provides evidence of the presence of bacterial biofilms and the type of bacteria present. Staphylococcus epidermidis bacteria interact with breast lipids to form the oxylipin 10-HOME (methyl (E)-10-hydroxy-8-octadecenoate). While many oxylipins are available commercially, 10-HOME has never been available. A novel method to synthesize 10-HOME has now been developed and optimized for two different versions. A deuterium-labelled “heavy” version and a non-isotopically enriched “normal” version will serve as a standard and reference for the detection of 10-HOME in human and other living animal tissue. Multiple FDA studies have found silicone breast implants to be safe and similar BII symptoms are present with other implants such as orthopedic implants greatly expanding the potential market. The underlying cause of implant related illnesses might not be related to the material of choice, but rather other mechanisms. The synthesized 10-Home oxylipin will be used to test for bacterial BII and other implant related illnesses.
Over 30,000 patients opt for breast implant explantation because of complications. Understanding the root cause and underlying molecular mechanism associated with BII and other implant illnesses will provide a better understanding of implant related disease. There is currently no way to diagnose BII except to rule out other inflammatory conditions or remove the implants. 10-HOME will help determine what molecules are associated with biofilm formation and provide important clinical insight. The methods and process to synthesize 10-HOME have been simplified and optimized to allow for commercial availability.
Implant related disease testing
Name : Tyson Rugenstein